Related Experiment Video
Updated: Aug 10, 2026
10:40
Measuring Neuromuscular Junction Functionality
Published on: August 6, 2017
Motor nerve ending disorder in myasthenia gravis
R D Roe1, W F Riker, F G Standaert
1Department of Neurology, Mt. Sinai School of Medicine, New York, NY.
Neurology
|February 1, 1988
Summary
Mild myasthenia gravis patients show a reduced capacity in their motor nerve endings to generate a neostigmine-induced postactivation repetition (PAR). This suggests a motor nerve ending disorder in myasthenia gravis.
Area of Science:
- Neurology
- Neurophysiology
- Pharmacology
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission.
- Understanding the specific site of neuromuscular junction dysfunction in mild MG is crucial.
Purpose of the Study:
- To investigate the function of motor nerve endings (MNEs) in mild myasthenia gravis.
- To assess the neostigmine-induced postactivation repetition (PAR) capacity in MNEs of myasthenic patients.
Main Methods:
- Comparison of MNEs in mild myasthenia gravis patients and healthy controls.
- Electrophysiological and contractile measurements of muscle response.
- Dose-response analysis of neostigmine-induced PAR.
Main Results:
- Mild myasthenic patients exhibited a diminished capacity to generate neostigmine-induced PAR compared to controls.
- The ability to transmit nerve impulse trains (20-200 Hz) was preserved in mild myasthenics.
- Dose-response analyses confirmed reduced pharmacologic responsiveness in myasthenia.
Conclusions:
- The findings indicate a disorder specifically within the motor nerve endings in mild myasthenia gravis.
- This MNE dysfunction contributes to the pathophysiology of the disease.
- Neostigmine-induced PAR serves as a sensitive indicator of MNE integrity.
More Related Videos
08:41Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
Published on: August 14, 2021
04:30Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
Published on: March 8, 2024
Related Concept Videos
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...